{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:40:46Z","timestamp":1784043646921,"version":"3.55.0"},"reference-count":158,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Myelodysplastic syndromes (MDS) are heterogeneous hematopoietic stem cell disorders defined by ineffective hematopoiesis, multilineage dysplasia, and risk of progression to acute myeloid leukemia. Improvements have been made to identify recurrent genetic mutations and their functional roles, but translating this into preclinical models is still difficult. Traditional murine systems lack the human-specific cytokine support and microenvironmental support that is necessary to reproduce MDS pathophysiology. Humanized mouse models, particularly those incorporating human cytokines (e.g., MISTRG, NSG-SGM3, NOG-EXL), immunodeficient backgrounds, and co-transplantation strategies, have improved the engraftment and differentiation of human hematopoietic stem and progenitor cells. These models allow the study of clonal evolution, mutation-specific disease dynamics, and response to therapies in vivo. However, difficulties persist, such as limited long-term engraftment, incomplete immune reconstruction, and limited possibilities of modeling early-stage or low-risk MDS. This review presents an overview of current humanized and genetically engineered mouse models suitable for studying MDS, evaluating their capacity to replicate disease complexity, preserve clonal architecture, and support translational research. We highlight the need to develop new approaches to improve the actual methodologies and propose future directions for standardization and improved clinical relevance.<\/jats:p>","DOI":"10.1038\/s41419-025-07861-0","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T18:21:57Z","timestamp":1752776517000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Humanized mouse models in MDS"],"prefix":"10.1038","volume":"16","author":[{"given":"Raluca","family":"Munteanu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Gulei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian Silviu","family":"Moldovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Azzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Belver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Feder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simina","family":"Pirv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca Dana","family":"Buzoianu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Mittelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Ghiaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hasserjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciprian","family":"Tomuleasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"7861_CR1","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/s41375-024-02181-2","volume":"38","author":"A Mina","year":"2024","unstructured":"Mina A, Pavletic S, Aplan PD. The evolution of preclinical models for myelodysplastic neoplasms. Leukemia. 2024;38:683\u201391.","journal-title":"Leukemia"},{"key":"7861_CR2","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/bjc.1977.107","volume":"35","author":"CR Franks","year":"1977","unstructured":"Franks CR, Bishop D, Balkwill FR, Oliver RT, Spector WG. Growth of acute myeloid leukaemia as discrete subcutaneous tumours in immune-deprived mice. Br J Cancer. 1977;35:697\u2013700.","journal-title":"Br J Cancer"},{"key":"7861_CR3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1182\/blood-2001-12-0188","volume":"100","author":"L Nilsson","year":"2002","unstructured":"Nilsson L, \u00c5strand-Grundstr\u00f6m I, Anderson K, Arvidsson I, Hokland P, Bryder D, et al. Involvement and functional impairment of the CD34\u2009+\u2009CD38\u2212Thy-1+ hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. Blood. 2002;100:259\u201367.","journal-title":"Blood"},{"key":"7861_CR4","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1182\/blood-2004-04-1518","volume":"104","author":"DMB Kerbauy","year":"2004","unstructured":"Kerbauy DMB, Lesnikov V, Torok-Storb B, Bryant E, Deeg HJ. Engraftment of distinct clonal MDS-derived hematopoietic precursors in NOD\/SCID-\u03b22-microglobulin-deficient mice after intramedullary transplantation of hematopoietic and stromal cells. Blood. 2004;104:2202\u20133.","journal-title":"Blood"},{"key":"7861_CR5","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/367645a0","volume":"367","author":"T Lapidot","year":"1994","unstructured":"Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645\u20138.","journal-title":"Nature"},{"key":"7861_CR6","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1038\/leu.2017.172","volume":"31","author":"K Rouault-Pierre","year":"2017","unstructured":"Rouault-Pierre K, Mian SA, Goulard M, Abarrategi A, Di Tulio A, Smith AE, et al. Preclinical modeling of myelodysplastic syndromes. Leukemia. 2017;31:2702\u20138.","journal-title":"Leukemia"},{"key":"7861_CR7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1158\/2643-3230.BCD-20-0161","volume":"2","author":"SA Mian","year":"2021","unstructured":"Mian SA, Abarrategi A, Kong KL, Rouault-Pierre K, Wood H, Oedekoven CA, et al. Ectopic humanized mesenchymal niche in mice enables robust engraftment of myelodysplastic stem cells. Blood Cancer Discov. 2021;2:135\u201345.","journal-title":"Blood Cancer Discov"},{"key":"7861_CR8","doi-asserted-by":"publisher","first-page":"959","DOI":"10.3324\/haematol.2017.183202","volume":"103","author":"M Krevvata","year":"2018","unstructured":"Krevvata M, Shan X, Zhou C, Dos Santos C, Habineza Ndikuyeze G, Secreto A, et al. Cytokines increase engraftment of human acute myeloid leukemia cells in immunocompromised mice but not engraftment of human myelodysplastic syndrome cells. Haematologica. 2018;103:959\u201371.","journal-title":"Haematologica"},{"key":"7861_CR9","doi-asserted-by":"publisher","first-page":"14993","DOI":"10.18632\/oncotarget.24538","volume":"9","author":"M Meunier","year":"2018","unstructured":"Meunier M, Dussiau C, Mauz N, Alary AS, Lefebvre C, Szymanski G, et al. Molecular dissection of engraftment in a xenograft model of myelodysplastic syndromes. Oncotarget. 2018;9:14993\u20135000.","journal-title":"Oncotarget"},{"key":"7861_CR10","doi-asserted-by":"publisher","unstructured":"Teodorescu P, Pasca S, Choi I, Shams C, Dalton WB, Gondek LP, et al. An accessible patient-derived xenograft model of low-risk myelodysplastic syndromes. Haematologica. 2023. https:\/\/doi.org\/10.3324\/haematol.2023.282967.","DOI":"10.3324\/haematol.2023.282967"},{"key":"7861_CR11","doi-asserted-by":"publisher","unstructured":"Coriu D, Stancioaica M-C. Moving low risk myelodysplastic syndromes from human to mice: is it truly that simple? Haematologica. 2023. https:\/\/doi.org\/10.3324\/haematol.2023.283652.","DOI":"10.3324\/haematol.2023.283652"},{"key":"7861_CR12","doi-asserted-by":"publisher","unstructured":"Villaume MT, Savona MR. Pathogenesis and inflammaging in myelodysplastic syndrome. Haematologica. 2024. https:\/\/doi.org\/10.3324\/haematol.2023.284944.","DOI":"10.3324\/haematol.2023.284944"},{"key":"7861_CR13","doi-asserted-by":"publisher","unstructured":"Chen B, Liu H, Liu Z, Yang F. Benefits and limitations of humanized mouse models for human red blood cell-related disease research. Front Hematol. 2023;1. https:\/\/doi.org\/10.3389\/frhem.2022.1062705.","DOI":"10.3389\/frhem.2022.1062705"},{"key":"7861_CR14","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1182\/blood-2015-01-624239","volume":"126","author":"T Zhou","year":"2015","unstructured":"Zhou T, Kinney MC, Scott LM, Zinkel SS, Rebel VI. Revisiting the case for genetically engineered mouse models in human myelodysplastic syndrome research. Blood. 2015;126:1057\u201368.","journal-title":"Blood"},{"key":"7861_CR15","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s10147-019-01462-6","volume":"24","author":"N Hosono","year":"2019","unstructured":"Hosono N. Genetic abnormalities and pathophysiology of MDS. Int J Clin Oncol. 2019;24:885\u201392.","journal-title":"Int J Clin Oncol"},{"key":"7861_CR16","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/ijlh.13284","volume":"42","author":"GC Caponetti","year":"2020","unstructured":"Caponetti GC, Bagg A. Mutations in myelodysplastic syndromes: core abnormalities and CHIPping away at the edges. Int J Lab Hematol. 2020;42:671\u201384.","journal-title":"Int J Lab Hematol"},{"key":"7861_CR17","doi-asserted-by":"publisher","unstructured":"Kontandreopoulou C-N, Kalopisis K, Viniou N-A, Diamantopoulos P. The genetics of myelodysplastic syndromes and the opportunities for tailored treatments. Front Oncol. 2022;12. https:\/\/doi.org\/10.3389\/fonc.2022.989483.","DOI":"10.3389\/fonc.2022.989483"},{"key":"7861_CR18","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/jha2.317","volume":"3","author":"MR Cook","year":"2022","unstructured":"Cook MR, Karp JE, Lai C. The spectrum of genetic mutations in myelodysplastic syndrome: should we update prognostication?. EJHaem. 2022;3:301\u201313.","journal-title":"EJHaem"},{"key":"7861_CR19","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1182\/blood-2013-03-492884","volume":"122","author":"L Malcovati","year":"2013","unstructured":"Malcovati L, Hellstr\u00f6m-Lindberg E, Bowen D, Ad\u00e8s L, Cermak J, del Ca\u00f1izo C, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122:2943\u201364.","journal-title":"Blood"},{"key":"7861_CR20","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","volume":"364","author":"R Bejar","year":"2011","unstructured":"Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364:2496\u2013506.","journal-title":"N Engl J Med"},{"key":"7861_CR21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/leu.2013.336","volume":"28","author":"T Haferlach","year":"2014","unstructured":"Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28:241\u20137.","journal-title":"Leukemia"},{"key":"7861_CR22","doi-asserted-by":"publisher","unstructured":"Jiang M, Chen M, Liu Q, Jin Z, Yang X, Zhang W. SF3B1 mutations in myelodysplastic syndromes: a potential therapeutic target for modulating the entire disease process. Front Oncol. 2023;13. https:\/\/doi.org\/10.3389\/fonc.2023.1116438.","DOI":"10.3389\/fonc.2023.1116438"},{"key":"7861_CR23","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.leukres.2009.03.005","volume":"33","author":"HG Drexler","year":"2009","unstructured":"Drexler HG, Dirks WG, MacLeod RAF. Many are called MDS cell lines: one is chosen. Leuk Res. 2009;33:1011\u20136.","journal-title":"Leuk Res"},{"key":"7861_CR24","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1182\/blood-2018-10-844621","volume":"133","author":"S Ogawa","year":"2019","unstructured":"Ogawa S. Genetics of MDS. Blood. 2019;133:1049\u201359.","journal-title":"Blood"},{"key":"7861_CR25","doi-asserted-by":"publisher","unstructured":"Liu W, Teodorescu P, Halene S, Ghiaur G. The coming of age of preclinical models of MDS. Front Oncol. 2022;12. https:\/\/doi.org\/10.3389\/fonc.2022.815037.","DOI":"10.3389\/fonc.2022.815037"},{"key":"7861_CR26","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3390\/curroncol31020044","volume":"31","author":"T Hasan","year":"2024","unstructured":"Hasan T, Pasala AR, Hassan D, Hanotaux J, Allan DS, Maganti HB. Homing and engraftment of hematopoietic stem cells following transplantation: a pre-clinical perspective. Current Oncol. 2024;31:603\u201316.","journal-title":"Current Oncol"},{"key":"7861_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/srep05290","volume":"4","author":"F Li","year":"2014","unstructured":"Li F, Cowley DO, Banner D, Holle E, Zhang L, Su L. Efficient genetic manipulation of the NOD-Rag1-\/-IL2RgammaC-null mouse by combining in vitro fertilization and CRISPR\/Cas9 technology. Sci Rep. 2014;4:5290.","journal-title":"Sci Rep"},{"key":"7861_CR28","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3389\/fgene.2019.00401","volume":"10","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Liu P, Xin Z, Shi C, Bai Y, Sun X, et al. Biological characteristics of severe combined immunodeficient mice produced by CRISPR\/Cas9-mediated Rag2 and IL2rg mutation. Front Genet. 2019;10:401.","journal-title":"Front Genet"},{"key":"7861_CR29","doi-asserted-by":"publisher","first-page":"e0209034","DOI":"10.1371\/journal.pone.0209034","volume":"13","author":"M Wunderlich","year":"2018","unstructured":"Wunderlich M, Chou F-S, Sexton C, Presicce P, Chougnet CA, Aliberti J, et al. Improved multilineage human hematopoietic reconstitution and function in NSGS mice. PLoS ONE. 2018;13:e0209034.","journal-title":"PLoS ONE"},{"key":"7861_CR30","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1182\/bloodadvances.2023010971","volume":"8","author":"L Wang","year":"2024","unstructured":"Wang L, Leach V, Muthusamy N, Byrd J, Long M. A CD3 humanized mouse model unmasked unique features of T-cell responses to bispecific antibody treatment. Blood Adv. 2024;8:470\u201381.","journal-title":"Blood Adv"},{"key":"7861_CR31","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.1158\/1538-7445.AM2022-5195","volume":"82","author":"X Yang","year":"2022","unstructured":"Yang X, Ju C, Zhang M, Zhao J. Abstract 5195: Humanized CD3E,D,G mice: an ideal model for efficacy study of CD3-bispecific antibodies. Cancer Res. 2022;82:5195.","journal-title":"Cancer Res"},{"key":"7861_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ebiom.2019.01.029","volume":"40","author":"Y Wu","year":"2019","unstructured":"Wu Y, Yu X-Z. Modelling CAR-T therapy in humanized mice. EBioMedicine. 2019;40:25\u201326.","journal-title":"EBioMedicine"},{"key":"7861_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06660-3","volume":"15","author":"S Liu","year":"2024","unstructured":"Liu S, Joshi K, Zhang L, Li W, Mack R, Runde A, et al. Caspase 8 deletion causes infection\/inflammation-induced bone marrow failure and MDS-like disease in mice. Cell Death Dis. 2024;15:278.","journal-title":"Cell Death Dis"},{"key":"7861_CR34","doi-asserted-by":"publisher","first-page":"e0173088","DOI":"10.1371\/journal.pone.0173088","volume":"12","author":"M Buszko","year":"2017","unstructured":"Buszko M, Cardini B, Oberhuber R, Oberhuber L, Jakic B, Beierfuss A, et al. Differential depletion of total T cells and regulatory T cells and prolonged allotransplant survival in CD3\u0190 humanized mice treated with polyclonal anti human thymocyte globulin. PLoS ONE. 2017;12:e0173088.","journal-title":"PLoS ONE"},{"key":"7861_CR35","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.3324\/haematol.2012.074823","volume":"98","author":"B Costantini","year":"2013","unstructured":"Costantini B, Kordasti SY, Kulasekararaj AG, Jiang J, Seidl T, Abellan PP, et al. The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome. Haematologica. 2013;98:1196\u2013205.","journal-title":"Haematologica"},{"key":"7861_CR36","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1182\/blood.V116.21.1860.1860","volume":"116","author":"HJ Bontkes","year":"2010","unstructured":"Bontkes HJ, Alhan C, Eeltink C, Westers TM, Ossenkoppele GJ, Van de Loosdrecht AA. Immunomodulatory effects of azacitidine treatment in high risk myelodysplastic syndrome. Blood. 2010;116:1860.","journal-title":"Blood"},{"key":"7861_CR37","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1182\/blood-2024-208684","volume":"144","author":"D Nguyen","year":"2024","unstructured":"Nguyen D, Ravandi F, Wang SA, Jorgensen JL, WANG W, Loghavi S, et al. Updated results from a phase II study of vibecotamab, a CD3-CD123 bispecific T-cell engaging antibody, for MDS or CMML after hypomethylating failure and in MRD-positive AML. Blood. 2024;144:1007.","journal-title":"Blood"},{"key":"7861_CR38","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1182\/blood.V130.Suppl_1.637.637","volume":"130","author":"GL Uy","year":"2017","unstructured":"Uy GL, Godwin J, Rettig MP, Vey N, Foster M, Arellano ML, et al. Preliminary results of a phase 1 study of flotetuzumab, a CD123 x CD3 Bispecific Dart\u00ae protein, in patients with relapsed\/refractory acute myeloid leukemia and myelodysplastic syndrome. Blood. 2017;130:637.","journal-title":"Blood"},{"key":"7861_CR39","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.3390\/jcm11051333","volume":"11","author":"SP Barwe","year":"2022","unstructured":"Barwe SP, Kisielewski A, Bonvini E, Muth J, Davidson-Moncada J, Kolb EA, et al. Efficacy of flotetuzumab in combination with cytarabine in patient-derived xenograft models of pediatric acute myeloid leukemia. J Clin Med. 2022;11:1333.","journal-title":"J Clin Med"},{"key":"7861_CR40","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1538\/expanim.22-0012","volume":"71","author":"R Zhang","year":"2022","unstructured":"Zhang R, Zhang J, Zhou X, Zhao A, Yu C. The establishment and application of CD3E humanized mice in immunotherapy. Exp Anim. 2022;71:22\u20130012.","journal-title":"Exp Anim"},{"key":"7861_CR41","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1161\/HYPERTENSIONAHA.116.07237","volume":"68","author":"HA Itani","year":"2016","unstructured":"Itani HA, McMaster WG, Saleh MA, Nazarewicz RR, Mikolajczyk TP, Kaszuba AM, et al. Activation of human T cells in hypertension. Hypertension. 2016;68:123\u201332.","journal-title":"Hypertension"},{"key":"7861_CR42","doi-asserted-by":"publisher","unstructured":"Coats JS, Baez I, Stoian C, Milford T-AM, Zhang X, Francis OL, et al. Expression of exogenous cytokine in patient-derived xenografts via injection with a cytokine-transduced stromal cell line. J Vis Exp. 2017. https:\/\/doi.org\/10.3791\/55384.","DOI":"10.3791\/55384"},{"key":"7861_CR43","doi-asserted-by":"publisher","unstructured":"Wang J, Erlacher M, Fernandez-Orth J. The role of inflammation in hematopoiesis and bone marrow failure: What can we learn from mouse models? Front Immunol. 2022;13. https:\/\/doi.org\/10.3389\/fimmu.2022.951937.","DOI":"10.3389\/fimmu.2022.951937"},{"key":"7861_CR44","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.it.2020.06.004","volume":"41","author":"Y Saito","year":"2020","unstructured":"Saito Y, Shultz LD, Ishikawa F. Understanding normal and malignant human hematopoiesis using next-generation humanized mice. Trends Immunol. 2020;41:706\u201320.","journal-title":"Trends Immunol"},{"key":"7861_CR45","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41590-019-0416-z","volume":"20","author":"TM Allen","year":"2019","unstructured":"Allen TM, Brehm MA, Bridges S, Ferguson S, Kumar P, Mirochnitchenko O, et al. Humanized immune system mouse models: progress, challenges and opportunities. Nat Immunol. 2019;20:770\u20134.","journal-title":"Nat Immunol"},{"key":"7861_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08166-x","volume":"10","author":"Y Song","year":"2019","unstructured":"Song Y, Rongvaux A, Taylor A, Jiang T, Tebaldi T, Balasubramanian K, et al. A highly efficient and faithful MDS patient-derived xenotransplantation model for pre-clinical studies. Nat Commun. 2019;10:366.","journal-title":"Nat Commun"},{"key":"7861_CR47","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/cmi.2012.2","volume":"9","author":"R Ito","year":"2012","unstructured":"Ito R, Takahashi T, Katano I, Ito M. Current advances in humanized mouse models. Cell Mol Immunol. 2012;9:208\u201314.","journal-title":"Cell Mol Immunol"},{"key":"7861_CR48","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1177\/03009858231222216","volume":"61","author":"E Willis","year":"2024","unstructured":"Willis E, Verrelle J, Banerjee E, Assenmacher C-A, Tarrant JC, Skuli N, et al. Humanization with CD34-positive hematopoietic stem cells in NOG-EXL mice results in improved long-term survival and less severe myeloid cell hyperactivation phenotype relative to NSG-SGM3 mice. Vet Pathol. 2024;61:664\u201374.","journal-title":"Vet Pathol"},{"key":"7861_CR49","doi-asserted-by":"publisher","first-page":"921","DOI":"10.3324\/haematol.2018.193847","volume":"103","author":"E Griessinger","year":"2018","unstructured":"Griessinger E, Andreeff M. NSG-S mice for acute myeloid leukemia, yes. For myelodysplastic syndrome, no. Haematologica. 2018;103:921\u20133.","journal-title":"Haematologica"},{"key":"7861_CR50","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.3390\/microorganisms11061548","volume":"11","author":"H Gutierrez-Barbosa","year":"2023","unstructured":"Gutierrez-Barbosa H, Medina-Moreno S, Perdomo-Celis F, Davis H, Coronel-Ruiz C, Zapata JC, et al. A comparison of lymphoid and myeloid cells derived from human hematopoietic stem cells xenografted into NOD-derived mouse strains. Microorganisms. 2023;11:1548.","journal-title":"Microorganisms"},{"key":"7861_CR51","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13287-024-03799-w","volume":"15","author":"R Ito","year":"2024","unstructured":"Ito R, Ohno Y, Mu Y, Ka Y, Ito S, Emi-Sugie M, et al. Improvement of multilineage hematopoiesis in hematopoietic stem cell-transferred c-kit mutant NOG-EXL humanized mice. Stem Cell Res Ther. 2024;15:182.","journal-title":"Stem Cell Res Ther"},{"key":"7861_CR52","doi-asserted-by":"publisher","unstructured":"Maser I-P, Hoves S, Bayer C, Heidkamp G, Nimmerjahn F, Eckmann J, et al. The tumor milieu promotes functional human tumor-resident plasmacytoid dendritic cells in humanized mouse models. Front Immunol. 2020;11. https:\/\/doi.org\/10.3389\/fimmu.2020.02082.","DOI":"10.3389\/fimmu.2020.02082"},{"key":"7861_CR53","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1089\/scd.2016.0193","volume":"25","author":"DJ Smith","year":"2016","unstructured":"Smith DJ, Lin LJ, Moon H, Pham AT, Wang X, Liu S, et al. Propagating humanized BLT mice for the study of human immunology and immunotherapy. Stem Cells Dev. 2016;25:1863\u201373.","journal-title":"Stem Cells Dev"},{"key":"7861_CR54","doi-asserted-by":"crossref","unstructured":"Aryee K-E, Shultz LD, Brehm MA. Immunodeficient mouse model for human hematopoietic stem cell engraftment and immune system development. Methods Mol Biol. 2014;118:267\u201378.","DOI":"10.1007\/978-1-4939-1133-2_18"},{"key":"7861_CR55","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.trsl.2019.04.007","volume":"210","author":"H Yan","year":"2019","unstructured":"Yan H, Semple KM, Gonzal\u00e9z CM, Howard KE. Bone marrow-liver-thymus (BLT) immune humanized mice as a model to predict cytokine release syndrome. Translational Res. 2019;210:43\u201356.","journal-title":"Translational Res"},{"key":"7861_CR56","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1038\/s41375-021-01259-5","volume":"35","author":"E Coppin","year":"2021","unstructured":"Coppin E, Sundarasetty BS, Rahmig S, Blume J, Verheyden NA, Bahlmann F, et al. Enhanced differentiation of functional human T cells in NSGW41 mice with tissue-specific expression of human interleukin-7. Leukemia. 2021;35:3561\u20137.","journal-title":"Leukemia"},{"key":"7861_CR57","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41571-022-00721-2","volume":"20","author":"J Chuprin","year":"2023","unstructured":"Chuprin J, Buettner H, Seedhom MO, Greiner DL, Keck JG, Ishikawa F, et al. Humanized mouse models for immuno-oncology research. Nat Rev Clin Oncol. 2023;20:192\u2013206.","journal-title":"Nat Rev Clin Oncol"},{"key":"7861_CR58","doi-asserted-by":"publisher","first-page":"6093","DOI":"10.1182\/bloodadvances.2021006591","volume":"6","author":"S Kim","year":"2022","unstructured":"Kim S, Lee SW, Koh J-Y, Choi D, Heo M, Chung J-Y, et al. A single administration of hIL-7-hyFc induces long-lasting T-cell expansion with maintained effector functions. Blood Adv. 2022;6:6093\u2013107.","journal-title":"Blood Adv"},{"key":"7861_CR59","doi-asserted-by":"publisher","unstructured":"Tian H, Lyu Y, Yang Y-G, Hu Z. Humanized rodent models for cancer research. Front Oncol. 2020;10. https:\/\/doi.org\/10.3389\/fonc.2020.01696.","DOI":"10.3389\/fonc.2020.01696"},{"key":"7861_CR60","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1182\/blood.V92.7.2556","volume":"92","author":"JCM van der Loo","year":"1998","unstructured":"van der Loo JCM, Hanenberg H, Cooper RJ, Luo F-Y, Lazaridis EN, Williams DA. Nonobese diabetic\/severe combined immunodeficiency (NOD\/SCID) mouse as a model system to study the engraftment and mobilization of human peripheral blood stem cells. Blood. 1998;92:2556\u201370.","journal-title":"Blood"},{"key":"7861_CR61","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.bbmt.2010.12.697","volume":"17","author":"J Andrade","year":"2011","unstructured":"Andrade J, Ge S, Symbatyan G, Rosol MS, Olch AJ, Crooks GM. Effects of sublethal irradiation on patterns of engraftment after murine bone marrow transplantation. Biology Blood Marrow Transplant. 2011;17:608\u201319.","journal-title":"Biology Blood Marrow Transplant"},{"key":"7861_CR62","doi-asserted-by":"publisher","unstructured":"Zhang Q, Rydstr\u00f6m A, Hidalgo I, Cammenga J, Nilsson AR. Medium-dose irradiation impairs long-term hematopoietic stem cell functionality and hematopoietic recovery to cytotoxic stress. 2024. https:\/\/doi.org\/10.1101\/2024.10.29.620607.","DOI":"10.1101\/2024.10.29.620607"},{"key":"7861_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-71307-4","volume":"14","author":"K Lee","year":"2024","unstructured":"Lee K, Dissanayake W, MacLiesh M, Hong C-L, Yin Z, Kawano Y, et al. Ultralow-dose irradiation enables engraftment and intravital tracking of disease initiating niches in clonal hematopoiesis. Sci Rep. 2024;14:20486.","journal-title":"Sci Rep"},{"key":"7861_CR64","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1182\/blood-2023-189794","volume":"142","author":"A Antypiuk","year":"2023","unstructured":"Antypiuk A, Martinez A, Schaeper U, Platzbecker U, Vinchi F. Myelodysplastic syndromes benefit from iron-restricted bone marrow transplant in preclinical mouse model. Blood. 2023;142:2462.","journal-title":"Blood"},{"key":"7861_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2020.100159","volume":"1","author":"E Montecino-Rodriguez","year":"2020","unstructured":"Montecino-Rodriguez E, Dorshkind K. Use of busulfan to condition mice for bone marrow transplantation. STAR Protoc. 2020;1:100159.","journal-title":"STAR Protoc"},{"key":"7861_CR66","doi-asserted-by":"publisher","unstructured":"Garcia-Perez L, van Roon L, Schilham MW, Lankester AC, Pike-Overzet K, Staal FJT. Combining mobilizing agents with busulfan to reduce chemotherapy-based conditioning for hematopoietic stem cell transplantation. Cells. 2021;10. https:\/\/doi.org\/10.3390\/cells10051077.","DOI":"10.3390\/cells10051077"},{"key":"7861_CR67","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/10915818221148130","volume":"42","author":"C Ballesteros","year":"2023","unstructured":"Ballesteros C, Wong K, Abrahim MA, Li C, Authier S. Model characterization: total body irradiation or busulfan for conditioning in human cell therapy toxicology and tumorigenicity studies using NOD\/SCID\/IL2R\u03b3null (NSG) mice. Int J Toxicol. 2023;42:219\u201331.","journal-title":"Int J Toxicol"},{"key":"7861_CR68","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/0027-5107(87)90057-1","volume":"176","author":"LR Bucci","year":"1987","unstructured":"Bucci LR, Meistrich ML. Effects of busulfan on murine spermatogenesis: cytotoxicity, sterility, sperm abnormalities, and dominant lethal mutations. Mutat Res. 1987;176:259\u201368.","journal-title":"Mutat Res"},{"key":"7861_CR69","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/ilar.52.1.24","volume":"52","author":"DW Threadgill","year":"2011","unstructured":"Threadgill DW, Miller DR, Churchill GA, de Villena FP-M. The collaborative cross: a recombinant inbred mouse population for the systems genetic era. ILAR J. 2011;52:24\u201331.","journal-title":"ILAR J"},{"key":"7861_CR70","doi-asserted-by":"crossref","unstructured":"Churchill GA, Airey DC, Allayee H, Angel JM, Attie AD, Beatty J, et al. The Collaborative Cross, a community resource for the genetic analysis of complex traits. Nat Genet. 2004;36:1133\u20137.","DOI":"10.1038\/ng1104-1133"},{"key":"7861_CR71","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/ame2.12168","volume":"4","author":"W Li","year":"2021","unstructured":"Li W, Cao L, Li M, Yang X, Zhang W, Song Z, et al. Novel spontaneous myelodysplastic syndrome mouse model. Animal Model Exp Med. 2021;4:169\u201380.","journal-title":"Animal Model Exp Med"},{"key":"7861_CR72","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/bjh.17372","volume":"193","author":"S Shafiee","year":"2021","unstructured":"Shafiee S, Gelebart P, Popa M, Helles\u00f8y M, Hovland R, Brendsdal Forthun R, et al. Preclinical characterisation and development of a novel myelodysplastic syndrome-derived cell line. Br J Haematol. 2021;193:415\u20139.","journal-title":"Br J Haematol"},{"key":"7861_CR73","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.leukres.2011.03.007","volume":"35","author":"J Wegrzyn","year":"2011","unstructured":"Wegrzyn J, Lam JC, Karsan A. Mouse models of myelodysplastic syndromes. Leuk Res. 2011;35:853\u201362.","journal-title":"Leuk Res"},{"key":"7861_CR74","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/ame2.12144","volume":"4","author":"W Li","year":"2021","unstructured":"Li W, Li M, Yang X, Zhang W, Cao L, Gao R. Summary of animal models of myelodysplastic syndrome. Animal Model Exp Med. 2021;4:71\u201376.","journal-title":"Animal Model Exp Med"},{"key":"7861_CR75","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1182\/blood.V100.1.238","volume":"100","author":"SC Kogan","year":"2002","unstructured":"Kogan SC, Ward JM, Anver MR, Berman JJ, Brayton C, Cardiff RD, et al. Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood. 2002;100:238\u201345.","journal-title":"Blood"},{"key":"7861_CR76","doi-asserted-by":"publisher","unstructured":"Herrmann K, Jayne K, editors. Animal experimentation: working towards a paradigm change. Brill Publishing House, Leiden (The Netherlands) and Boston (USA); 2019. https:\/\/doi.org\/10.1163\/9789004391192.","DOI":"10.1163\/9789004391192"},{"key":"7861_CR77","doi-asserted-by":"crossref","unstructured":"Huang W, Percie du Sert N, Vollert J, Rice ASC. General principles of preclinical study design. Handb Exp Pharmacol. 2020;257:55\u201369.","DOI":"10.1007\/164_2019_277"},{"key":"7861_CR78","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201708662","volume":"12","author":"R Stripecke","year":"2020","unstructured":"Stripecke R, M\u00fcnz C, Schuringa JJ, Bissig K-D, Soper B, Meeham T, et al. Innovations, challenges, and minimal information for standardization of humanized mice. EMBO Mol Med. 2020;12:e8662.","journal-title":"EMBO Mol Med"},{"key":"7861_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s41073-019-0069-3","volume":"4","author":"K Hair","year":"2019","unstructured":"Hair K, Macleod MR, Sena ES. A randomised controlled trial of an intervention to improve compliance with the ARRIVE guidelines (IICARus). Res Integr Peer Rev. 2019;4:12.","journal-title":"Res Integr Peer Rev"},{"key":"7861_CR80","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/0023677217724823","volume":"52","author":"AJ Smith","year":"2018","unstructured":"Smith AJ, Clutton RE, Lilley E, Hansen KEA, Brattelid T. PREPARE: guidelines for planning animal research and testing. Lab Anim. 2018;52:135\u201341.","journal-title":"Lab Anim"},{"key":"7861_CR81","doi-asserted-by":"publisher","first-page":"e98856","DOI":"10.1371\/journal.pone.0098856","volume":"9","author":"JA Hirst","year":"2014","unstructured":"Hirst JA, Howick J, Aronson JK, Roberts N, Perera R, Koshiaris C, et al. The need for randomization in animal trials: an overview of systematic reviews. PLoS ONE. 2014;9:e98856.","journal-title":"PLoS ONE"},{"key":"7861_CR82","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1182\/blood-2024-211908","volume":"144","author":"A Baassiri","year":"2024","unstructured":"Baassiri A, Maziarz J, Blackburn HN, Maul-Newby H, VanOudenhove J, Zhang X, et al. MISTRG6kitW41: enhanced engraftment in a cytokine humanized patient-derived xenotransplantation mouse model. Blood. 2024;144:1815.","journal-title":"Blood"},{"key":"7861_CR83","doi-asserted-by":"publisher","first-page":"4496","DOI":"10.1182\/blood-2022-158149","volume":"140","author":"G Dal Collo","year":"2022","unstructured":"Dal Collo G, van Hoven-Beijen A, He Y, Muller YM, Wang Y, Zhao J, et al. Novel anti-CD117 antibodies for rapid and efficient hematopoietic stem cell depletion and safe bone marrow conditioning. Blood. 2022;140:4496\u20137.","journal-title":"Blood"},{"key":"7861_CR84","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1038\/s41375-022-01728-5","volume":"36","author":"S Huber","year":"2022","unstructured":"Huber S, Haferlach T, Meggendorfer M, Hutter S, Hoermann G, Baer C, et al. SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis. Leukemia. 2022;36:2894\u2013902.","journal-title":"Leukemia"},{"key":"7861_CR85","doi-asserted-by":"publisher","unstructured":"Zhang L, Chen K, Li Y, Chen Q, Shi W, Ji T, et al. Clinical outcomes and characteristics of patients with TP53 -mutated myelodysplastic syndromes. Hematology. 2023;28. https:\/\/doi.org\/10.1080\/16078454.2023.2181773.","DOI":"10.1080\/16078454.2023.2181773"},{"key":"7861_CR86","doi-asserted-by":"publisher","unstructured":"Baranwal A, Gurney M, Basmaci R, Katamesh B, He R, Viswanatha DS, et al. Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms. Haematologica. 2024. https:\/\/doi.org\/10.3324\/haematol.2023.284185.","DOI":"10.3324\/haematol.2023.284185"},{"key":"7861_CR87","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/diseases10020033","volume":"10","author":"GP Barakos","year":"2022","unstructured":"Barakos GP, Hatzimichael E. Microenvironmental features driving immune evasion in myelodysplastic syndromes and acute myeloid leukemia. Diseases. 2022;10:33.","journal-title":"Diseases"},{"key":"7861_CR88","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3390\/cancers17050749","volume":"17","author":"A Tasis","year":"2025","unstructured":"Tasis A, Spyropoulos T, Mitroulis I. The emerging role of CD8\u2009+\u2009T cells in shaping treatment outcomes of patients with MDS and AML. Cancers. 2025;17:749.","journal-title":"Cancers"},{"key":"7861_CR89","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41590-020-0663-z","volume":"21","author":"Muto","year":"2020","unstructured":"Muto, Walker T, Choi CS, Hueneman K, Smith MA K, Gul Z, et al. Adaptive response to inflammation contributes to sustained myelopoiesis and confers a competitive advantage in myelodysplastic syndrome HSCs. Nat Immunol. 2020;21:535\u201345.","journal-title":"Nat Immunol"},{"key":"7861_CR90","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.1172\/JCI67580","volume":"123","author":"X Chen","year":"2013","unstructured":"Chen X, Eksioglu EA, Zhou J, Zhang L, Djeu J, Fortenbery N, et al. Induction of myelodysplasia by myeloid-derived suppressor cells. J Clin Investig. 2013;123:4595\u2013611.","journal-title":"J Clin Investig"},{"key":"7861_CR91","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1182\/blood-2004-12-4794","volume":"106","author":"Y-W Lin","year":"2005","unstructured":"Lin Y-W, Slape C, Zhang Z, Aplan PD. NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia. Blood. 2005;106:287\u201395.","journal-title":"Blood"},{"key":"7861_CR92","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1002\/cncr.33745","volume":"127","author":"R Kanagal-Shamanna","year":"2021","unstructured":"Kanagal-Shamanna R, Montalban-Bravo G, Sasaki K, Darbaniyan F, Jabbour E, Bueso-Ramos C, et al. Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. Cancer. 2021;127:3552\u201365.","journal-title":"Cancer"},{"key":"7861_CR93","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/leu.2016.251","volume":"31","author":"A Mupo","year":"2017","unstructured":"Mupo A, Seiler M, Sathiaseelan V, Pance A, Yang Y, Agrawal AA, et al. Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts. Leukemia. 2017;31:720\u20137.","journal-title":"Leukemia"},{"key":"7861_CR94","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3324\/haematol.2019.233320","volume":"105","author":"C C\u00f4me","year":"2020","unstructured":"C\u00f4me C, Balhuizen A, Bonnet D, Porse BT. Myelodysplastic syndrome patient-derived xenografts: from no options to many. Haematologica. 2020;105:864\u20139.","journal-title":"Haematologica"},{"key":"7861_CR95","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1038\/s41375-018-0152-7","volume":"32","author":"Y Liang","year":"2018","unstructured":"Liang Y, Tebaldi T, Rejeski K, Joshi P, Stefani G, Taylor A, et al. SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells. Leukemia. 2018;32:2659\u201371.","journal-title":"Leukemia"},{"key":"7861_CR96","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1182\/blood-2012-02-412296","volume":"120","author":"S-J Wu","year":"2012","unstructured":"Wu S-J, Kuo Y-Y, Hou H-A, Li L-Y, Tseng M-H, Huang C-F, et al. The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. Blood. 2012;120:3106\u201311.","journal-title":"Blood"},{"key":"7861_CR97","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1080\/10245332.2018.1471794","volume":"23","author":"P Arbab Jafari","year":"2018","unstructured":"Arbab Jafari P, Ayatollahi H, Sadeghi R, Sheikhi M, Asghari A. Prognostic significance of SRSF2 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: a meta-analysis. Hematology. 2018;23:778\u201384.","journal-title":"Hematology"},{"key":"7861_CR98","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/ajh.26984","volume":"98","author":"G Garcia-Manero","year":"2023","unstructured":"Garcia-Manero G. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:1307\u201325.","journal-title":"Am J Hematol"},{"key":"7861_CR99","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.stemcr.2016.06.002","volume":"7","author":"T Velasco-Hernandez","year":"2016","unstructured":"Velasco-Hernandez T, S\u00e4w\u00e9n P, Bryder D, Cammenga J. Potential pitfalls of the Mx1-Cre system: implications for experimental modeling of normal and malignant hematopoiesis. Stem Cell Rep. 2016;7:11\u201318.","journal-title":"Stem Cell Rep"},{"key":"7861_CR100","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.ccell.2015.04.006","volume":"27","author":"E Kim","year":"2015","unstructured":"Kim E, Ilagan JO, Liang Y, Daubner GM, Lee SC-W, Ramakrishnan A, et al. SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell. 2015;27:617\u201330.","journal-title":"Cancer Cell"},{"key":"7861_CR101","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13000-021-01162-8","volume":"16","author":"P Niparuck","year":"2021","unstructured":"Niparuck P, Police P, Noikongdee P, Siriputtanapong K, Limsuwanachot N, Rerkamnuaychoke B, et al. TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Diagn Pathol. 2021;16:100.","journal-title":"Diagn Pathol"},{"key":"7861_CR102","doi-asserted-by":"publisher","first-page":"5392","DOI":"10.3390\/cancers13215392","volume":"13","author":"Y Jiang","year":"2021","unstructured":"Jiang Y, Gao S-J, Soubise B, Douet-Guilbert N, Liu Z-L, Troadec M-B. TP53 in myelodysplastic syndromes. Cancers. 2021;13:5392.","journal-title":"Cancers"},{"key":"7861_CR103","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/cdd.2013.17","volume":"20","author":"W Hanel","year":"2013","unstructured":"Hanel W, Marchenko N, Xu S, Xiaofeng Yu S, Weng W, Moll U. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. Cell Death Differ. 2013;20:898\u2013909.","journal-title":"Cell Death Differ"},{"key":"7861_CR104","doi-asserted-by":"publisher","unstructured":"Sato H, Wheat JC, Steidl U, Ito K. DNMT3A and TET2 in the pre-leukemic phase of hematopoietic disorders. Front Oncol. 2016;6. https:\/\/doi.org\/10.3389\/fonc.2016.00187.","DOI":"10.3389\/fonc.2016.00187"},{"key":"7861_CR105","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1182\/blood-2014-08-594648","volume":"125","author":"A Mayle","year":"2015","unstructured":"Mayle A, Yang L, Rodriguez B, Zhou T, Chang E, Curry CV, et al. Dnmt3a loss predisposes murine hematopoietic stem cells to malignant transformation. Blood. 2015;125:629\u201338.","journal-title":"Blood"},{"key":"7861_CR106","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1158\/0008-5472.CAN-20-3033","volume":"81","author":"K Venugopal","year":"2021","unstructured":"Venugopal K, Feng Y, Shabashvili D, Guryanova OA. Alterations to DNMT3A in hematologic malignancies. Cancer Res. 2021;81:254\u201363.","journal-title":"Cancer Res"},{"key":"7861_CR107","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1038\/s41375-020-0869-y","volume":"34","author":"D Midic","year":"2020","unstructured":"Midic D, Rinke J, Perner F, M\u00fcller V, Hinze A, Pester F, et al. Prevalence and dynamics of clonal hematopoiesis caused by leukemia-associated mutations in elderly individuals without hematologic disorders. Leukemia. 2020;34:2198\u2013205.","journal-title":"Leukemia"},{"key":"7861_CR108","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ng.3610","volume":"48","author":"X Zhang","year":"2016","unstructured":"Zhang X, Su J, Jeong M, Ko M, Huang Y, Park HJ, et al. DNMT3A and TET2 compete and cooperate to repress lineage-specific transcription factors in hematopoietic stem cells. Nat Genet. 2016;48:1014\u201323.","journal-title":"Nat Genet"},{"key":"7861_CR109","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1182\/blood-2013-12-541730","volume":"124","author":"L Xue","year":"2014","unstructured":"Xue L, Pulikkan JA, Valk PJM, Castilla LH. NrasG12D oncoprotein inhibits apoptosis of preleukemic cells expressing Cbf\u03b2-SMMHC via activation of MEK\/ERK axis. Blood. 2014;124:426\u201336.","journal-title":"Blood"},{"key":"7861_CR110","doi-asserted-by":"publisher","first-page":"82475","DOI":"10.18632\/oncotarget.19628","volume":"8","author":"Y Xu","year":"2017","unstructured":"Xu Y, Li Y, Xu Q, Chen Y, Lv N, Jing Y, et al. Implications of mutational spectrum in myelodysplastic syndromes based on targeted next-generation sequencing. Oncotarget. 2017;8:82475\u201390.","journal-title":"Oncotarget"},{"key":"7861_CR111","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1182\/blood-2010-04-280750","volume":"117","author":"Q Li","year":"2011","unstructured":"Li Q, Haigis KM, McDaniel A, Harding-Theobald E, Kogan SC, Akagi K, et al. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. Blood. 2011;117:2022\u201332.","journal-title":"Blood"},{"key":"7861_CR112","doi-asserted-by":"publisher","first-page":"6247","DOI":"10.1182\/blood-2011-07-328880","volume":"118","author":"SM Gough","year":"2011","unstructured":"Gough SM, Slape CI, Aplan PD. NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights. Blood. 2011;118:6247\u201357.","journal-title":"Blood"},{"key":"7861_CR113","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3343\/alm.2024.0190","volume":"45","author":"M-S Park","year":"2025","unstructured":"Park M-S, Kim B, Jang JH, Jung CW, Kim H-J, Kim H-Y. Rare non-cryptic NUP98 rearrangements associated with myeloid neoplasms and their poor prognostic impact. Ann Lab Med. 2025;45:53\u201361.","journal-title":"Ann Lab Med"},{"key":"7861_CR114","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/leu.2010.20","volume":"24","author":"J Boultwood","year":"2010","unstructured":"Boultwood J, Perry J, Pellagatti A, Fernandez-Mercado M, Fernandez-Santamaria C, Calasanz MJ, et al. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia. 2010;24:1062\u20135.","journal-title":"Leukemia"},{"key":"7861_CR115","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1756-8722-5-12","volume":"5","author":"V Gelsi-Boyer","year":"2012","unstructured":"Gelsi-Boyer V, Brecqueville M, Devillier R, Murati A, Mozziconacci M-J, Birnbaum D. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol. 2012;5:12.","journal-title":"J Hematol Oncol"},{"key":"7861_CR116","doi-asserted-by":"publisher","first-page":"4627","DOI":"10.1172\/JCI70739","volume":"123","author":"D Inoue","year":"2013","unstructured":"Inoue D, Kitaura J, Togami K, Nishimura K, Enomoto Y, Uchida T, et al. Myelodysplastic syndromes are induced by histone methylation\u00e2\u20ac\u201caltering ASXL1 mutations. J Clin Investig. 2013;123:4627\u201340.","journal-title":"J Clin Investig"},{"key":"7861_CR117","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1038\/s41375-022-01584-3","volume":"36","author":"M Kaisrlikova","year":"2022","unstructured":"Kaisrlikova M, Vesela J, Kundrat D, Votavova H, Dostalova Merkerova M, Krejcik Z, et al. RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS. Leukemia. 2022;36:1898\u2013906.","journal-title":"Leukemia"},{"key":"7861_CR118","doi-asserted-by":"publisher","unstructured":"Illango J, Sreekantan Nair A, Gor R, Wijeratne Fernando R, Malik M, Siddiqui NA, et al. A systematic review of the role of runt-related transcription factor 1 (RUNX1) in the pathogenesis of hematological malignancies in patients with inherited bone marrow failure syndromes. Cureus. 2022. https:\/\/doi.org\/10.7759\/cureus.25372.","DOI":"10.7759\/cureus.25372"},{"key":"7861_CR119","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/ng.1031","volume":"44","author":"TA Graubert","year":"2012","unstructured":"Graubert TA, Shen D, Ding L, Okeyo-Owuor T, Lunn CL, Shao J, et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet. 2012;44:53\u201357.","journal-title":"Nat Genet"},{"key":"7861_CR120","doi-asserted-by":"publisher","unstructured":"Wu S-J, Tang J-L, Lin C-T, Kuo Y-Y, Li L-Y, Tseng M-H, et al. Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression. Am J Hematol. 2013;88. https:\/\/doi.org\/10.1002\/ajh.23541.","DOI":"10.1002\/ajh.23541"},{"key":"7861_CR121","doi-asserted-by":"publisher","unstructured":"Fei DL, Zhen T, Durham B, Ferrarone J, Zhang T, Garrett L, et al. Impaired hematopoiesis and leukemia development in mice with a conditional knock-in allele of a mutant splicing factor gene U2af1. Proc Natl Acad Sci USA. 2018;115. https:\/\/doi.org\/10.1073\/pnas.1812669115.","DOI":"10.1073\/pnas.1812669115"},{"key":"7861_CR122","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.3390\/cells9071639","volume":"9","author":"J Rinke","year":"2020","unstructured":"Rinke J, Chase A, Cross NCP, Hochhaus A, Ernst T. EZH2 in myeloid malignancies. Cells. 2020;9:1639.","journal-title":"Cells"},{"key":"7861_CR123","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1038\/leu.2017.190","volume":"31","author":"J Rinke","year":"2017","unstructured":"Rinke J, M\u00fcller JP, Blaess MF, Chase A, Meggendorfer M, Sch\u00e4fer V, et al. Molecular characterization of EZH2 mutant patients with myelodysplastic\/myeloproliferative neoplasms. Leukemia. 2017;31:1936\u201343.","journal-title":"Leukemia"},{"key":"7861_CR124","doi-asserted-by":"publisher","unstructured":"Ling VY, Saw J, Tremblay CS, Sonderegger SE, Toulmin E, Boyle J, et al. Attenuated acceleration to leukemia after Ezh2 loss in Nup98-HoxD13 (NHD13) myelodysplastic syndrome. Hemasphere. 2019;3. https:\/\/doi.org\/10.1097\/HS9.0000000000000277.","DOI":"10.1097\/HS9.0000000000000277"},{"key":"7861_CR125","doi-asserted-by":"publisher","first-page":"e39909","DOI":"10.1097\/MD.0000000000039909","volume":"103","author":"H B\u00fclb\u00fcl","year":"2024","unstructured":"B\u00fclb\u00fcl H, Kaya \u00d6\u00d6, Karada\u011f FK, Olgun A, Demirci Z, Ceylan C. Prognostic impact of next-generation sequencing on myelodysplastic syndrome: a single-center experience. Medicine. 2024;103:e39909.","journal-title":"Medicine"},{"key":"7861_CR126","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.ccell.2016.08.013","volume":"30","author":"D Inoue","year":"2016","unstructured":"Inoue D, Abdel-Wahab O. Modeling SF3B1 mutations in cancer: advances, challenges, and opportunities. Cancer Cell. 2016;30:371\u20133.","journal-title":"Cancer Cell"},{"key":"7861_CR127","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1182\/blood.V126.23.1649.1649","volume":"126","author":"A Kon","year":"2015","unstructured":"Kon A, Yamazaki S, Ota Y, Kataoka K, Shiozawa Y, Morita M, et al. Srsf2 P95H mutation causes impaired stem cell repopulation and hematopoietic differentiation in mice. Blood. 2015;126:1649.","journal-title":"Blood"},{"key":"7861_CR128","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1182\/blood-2018-04-845602","volume":"132","author":"MF Smeets","year":"2018","unstructured":"Smeets MF, Tan SY, Xu JJ, Anande G, Unnikrishnan A, Chalk AM, et al. Srsf2 P95H initiates myeloid bias and myelodysplastic\/myeloproliferative syndrome from hemopoietic stem cells. Blood. 2018;132:608\u201321.","journal-title":"Blood"},{"key":"7861_CR129","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1038\/s41375-022-01727-6","volume":"36","author":"JJ Xu","year":"2022","unstructured":"Xu JJ, Chalk AM, Wall M, Langdon WY, Smeets MF, Walkley CR. Srsf2P95H\/+ co-operates with loss of TET2 to promote myeloid bias and initiate a chronic myelomonocytic leukemia-like disease in mice. Leukemia. 2022;36:2883\u201393.","journal-title":"Leukemia"},{"key":"7861_CR130","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1182\/blood-2017-01-762393","volume":"131","author":"A Kon","year":"2018","unstructured":"Kon A, Yamazaki S, Nannya Y, Kataoka K, Ota Y, Nakagawa MM, et al. Physiological Srsf2 P95H expression causes impaired hematopoietic stem cell functions and aberrant RNA splicing in mice. Blood. 2018;131:621\u201335.","journal-title":"Blood"},{"key":"7861_CR131","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01276-y","volume":"15","author":"Z Bao","year":"2025","unstructured":"Bao Z, Li B, Qin T, Xu Z, Qu S, Jia Y, et al. Molecular characteristics and clinical implications of TP53 mutations in therapy-related myelodysplastic syndromes. Blood Cancer J. 2025;15:58.","journal-title":"Blood Cancer J"},{"key":"7861_CR132","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13045-023-01480-y","volume":"16","author":"W Bahaj","year":"2023","unstructured":"Bahaj W, Kewan T, Gurnari C, Durmaz A, Ponvilawan B, Pandit I, et al. Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia. J Hematol Oncol. 2023;16:91.","journal-title":"J Hematol Oncol"},{"key":"7861_CR133","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.gendis.2022.12.004","volume":"11","author":"Y Li","year":"2024","unstructured":"Li Y, Yang S, Yang S. Deficiency of Trp53 and Rb1 in myeloid cell lineage spontaneously develops acute myeloid leukemia in a mouse model. Genes Dis. 2024;11:4\u20136.","journal-title":"Genes Dis"},{"key":"7861_CR134","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1101\/gr.157529.113","volume":"24","author":"S Maegawa","year":"2014","unstructured":"Maegawa S, Gough SM, Watanabe-Okochi N, Lu Y, Zhang N, Castoro RJ, et al. Age-related epigenetic drift in the pathogenesis of MDS and AML. Genome Res. 2014;24:580\u201391.","journal-title":"Genome Res"},{"key":"7861_CR135","doi-asserted-by":"publisher","first-page":"4509","DOI":"10.1182\/blood-2010-12-325241","volume":"118","author":"Z Li","year":"2011","unstructured":"Li Z, Cai X, Cai C-L, Wang J, Zhang W, Petersen BE, et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood. 2011;118:4509\u201318.","journal-title":"Blood"},{"key":"7861_CR136","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1038\/s41375-022-01674-2","volume":"36","author":"C Garcia-Ruiz","year":"2022","unstructured":"Garcia-Ruiz C, Mart\u00ednez-Valiente C, Cord\u00f3n L, Liquori A, Fern\u00e1ndez-Gonz\u00e1lez R, Pericuesta E, et al. Concurrent Zrsr2 mutation and Tet2 loss promote myelodysplastic neoplasm in mice. Leukemia. 2022;36:2509\u201318.","journal-title":"Leukemia"},{"key":"7861_CR137","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01054-2","volume":"14","author":"D Alawieh","year":"2024","unstructured":"Alawieh D, Cysique-Foinlan L, Willekens C, Renneville A. RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives. Blood Cancer J. 2024;14:72.","journal-title":"Blood Cancer J"},{"key":"7861_CR138","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1182\/blood-2017-01-763219","volume":"130","author":"A Yoshimi","year":"2017","unstructured":"Yoshimi A, Balasis ME, Vedder A, Feldman K, Ma Y, Zhang H, et al. Robust patient-derived xenografts of MDS\/MPN overlap syndromes capture the unique characteristics of CMML and JMML. Blood. 2017;130:397\u2013407.","journal-title":"Blood"},{"key":"7861_CR139","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1073\/pnas.0307203101","volume":"101","author":"BS Braun","year":"2004","unstructured":"Braun BS, Tuveson DA, Kong N, Le DT, Kogan SC, Rozmus J, et al. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci USA. 2004;101:597\u2013602.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7861_CR140","doi-asserted-by":"publisher","first-page":"4616","DOI":"10.1182\/blood.V124.21.4616.4616","volume":"124","author":"H Xu","year":"2014","unstructured":"Xu H, Deblassio TR, Armstrong SA, Nimer S. Role of p21 in a mouse model of NUP98-HOXD13 fusion driven myelodysplastic syndromes (MDS). Blood. 2014;124:4616.","journal-title":"Blood"},{"key":"7861_CR141","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1182\/blood.V110.11.2650.2650","volume":"110","author":"CW Choi","year":"2007","unstructured":"Choi CW, Chung YJ, Slape C, Aplan PD. A NUP98-HOXD13 fusion gene impairs differentiation of T and B lymphocytes. Blood. 2007;110:2650.","journal-title":"Blood"},{"key":"7861_CR142","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood.V118.21.865.865","volume":"118","author":"SM Greenblatt","year":"2011","unstructured":"Greenblatt SM, Li L, Slape C, Novak RL, Duffield AS, Nguyen B, et al. Knock-in of a FLT3 internal tandem duplication mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia. Blood. 2011;118:865.","journal-title":"Blood"},{"key":"7861_CR143","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1182\/blood.V110.11.401.401","volume":"110","author":"YJ Chung","year":"2007","unstructured":"Chung YJ, Choi CW, Slape C, Fry T, Aplan PD. A NUP98-HOXD13 fusion gene induces a transplantable myelodysplastic syndrome in mice. Blood. 2007;110:401.","journal-title":"Blood"},{"key":"7861_CR144","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1084\/jem.20171151","volume":"215","author":"R Nagase","year":"2018","unstructured":"Nagase R, Inoue D, Pastore A, Fujino T, Hou H-A, Yamasaki N, et al. Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation. J Exp Med. 2018;215:1729\u201347.","journal-title":"J Exp Med"},{"key":"7861_CR145","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1182\/blood-2013-05-500272","volume":"123","author":"J Wang","year":"2014","unstructured":"Wang J, Li Z, He Y, Pan F, Chen S, Rhodes S, et al. Loss of Asxl1 leads to myelodysplastic syndrome\u2013like disease in mice. Blood. 2014;123:541\u201353.","journal-title":"Blood"},{"key":"7861_CR146","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1182\/blood.V122.21.2746.2746","volume":"122","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Yan X, Chen A, Sashida G, Xiao Z, Huang G. Modeling and targeting MLL-PTD\/RUNX1 related MDS\/AML in mouse. Blood. 2013;122:2746.","journal-title":"Blood"},{"key":"7861_CR147","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14060","volume":"8","author":"CL Shirai","year":"2017","unstructured":"Shirai CL, White BS, Tripathi M, Tapia R, Ley JN, Ndonwi M, et al. Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome. Nat Commun. 2017;8:14060.","journal-title":"Nat Commun"},{"key":"7861_CR148","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1111\/bjh.17534","volume":"193","author":"T Karantanos","year":"2021","unstructured":"Karantanos T, Gondek LP, Varadhan R, Moliterno AR, DeZern AE, Jones RJ, et al. Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome\/myeloproliferative neoplasm overlap syndromes. Br J Haematol. 2021;193:1142\u201350.","journal-title":"Br J Haematol"},{"key":"7861_CR149","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1182\/blood-2015-03-634428","volume":"126","author":"M Mochizuki-Kashio","year":"2015","unstructured":"Mochizuki-Kashio M, Aoyama K, Sashida G, Oshima M, Tomioka T, Muto T, et al. Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner. Blood. 2015;126:1172\u201383.","journal-title":"Blood"},{"key":"7861_CR150","doi-asserted-by":"publisher","unstructured":"Musheer Aalam SM, Viringipurampeer IA, Walb MC, Tryggestad EJ, Emperumal CP, Song J, et al. Characterization of transgenic NSG-SGM3 mouse model of precision radiation-induced chronic hyposalivation. Radiat Res. 2022;198. https:\/\/doi.org\/10.1667\/RADE-21-00237.1.","DOI":"10.1667\/RADE-21-00237.1"},{"key":"7861_CR151","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/nbt.2858","volume":"32","author":"A Rongvaux","year":"2014","unstructured":"Rongvaux A, Willinger T, Martinek J, Strowig T, Gearty SV, Teichmann LL, et al. Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol. 2014;32:364\u201372.","journal-title":"Nat Biotechnol"},{"key":"7861_CR152","doi-asserted-by":"crossref","unstructured":"Willis E, Verrelle J, Banerjee E, Assenmacher C-A, Tarrant JC, Skuli N, et al. 22 humanized NOG-EXL mice exhibit improved overall survival and less severe myeloid cell activation relative to humanized NSG-SGM3 mice. In: Regular and young investigator award abstracts. BMJ Publishing Group Ltd, London; 2023. pp. A24.","DOI":"10.1136\/jitc-2023-SITC2023.0022"},{"key":"7861_CR153","doi-asserted-by":"publisher","unstructured":"Chen J, Liao S, Xiao Z, Pan Q, Wang X, Shen K, et al. The development and improvement of immunodeficient mice and humanized immune system mouse models. Front Immunol. 2022;13. https:\/\/doi.org\/10.3389\/fimmu.2022.1007579.","DOI":"10.3389\/fimmu.2022.1007579"},{"key":"7861_CR154","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/j.1365-2249.2008.03753.x","volume":"154","author":"T Pearson","year":"2008","unstructured":"Pearson T, Shultz LD, Miller D, King M, Laning J, Fodor W, et al. Non-obese diabetic\u2013recombination activating gene-1 (NOD\u2013 Rag 1 null) interleukin (IL)-2 receptor common gamma chain (IL 2 r\u03b3 null) null mice: a radioresistant model for human lymphohaematopoietic engraftment. Clin Exp Immunol. 2008;154:270\u201384.","journal-title":"Clin Exp Immunol"},{"key":"7861_CR155","doi-asserted-by":"publisher","first-page":"27700","DOI":"10.1016\/S0021-9258(18)47042-1","volume":"269","author":"N Minegishi","year":"1994","unstructured":"Minegishi N, Minegishi M, Tsuchiya S, Fujie H, Nagai T, Hayashi N, et al. Erythropoietin-dependent induction of hemoglobin synthesis in a cytokine-dependent cell line M-TAT. J Biol Chem. 1994;269:27700\u20134.","journal-title":"J Biol Chem"},{"key":"7861_CR156","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1365-2141.1994.tb04904.x","volume":"87","author":"K Tohyama","year":"1994","unstructured":"Tohyama K, Tsutani H, Ueda T, Nakamura T, Yoshida Y. Establishment and characterization of a novel myeloid cell line from the bone marrow of a patient with the myelodysplastic syndrome. Br J Haematol. 1994;87:235\u201342.","journal-title":"Br J Haematol"},{"key":"7861_CR157","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/jcp.10095","volume":"191","author":"Y Mishima","year":"2002","unstructured":"Mishima Y, Terui Y, Mishima Y, Katsuyama M, Mori M, Tomizuka H, et al. New human myelodysplastic cell line, TER-3: G-CSF specific downregulation of Ca 2\u2009+\u2009\/calmodulin-dependent protein kinase IV. J Cell Physiol. 2002;191:183\u201390.","journal-title":"J Cell Physiol"},{"key":"7861_CR158","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1038\/s41375-018-0189-7","volume":"32","author":"J Kida","year":"2018","unstructured":"Kida J, Tsujioka T, Suemori S, Okamoto S, Sakakibara K, Takahata T, et al. An MDS-derived cell line and a series of its sublines serve as an in vitro model for the leukemic evolution of MDS. Leukemia. 2018;32:1846\u201350.","journal-title":"Leukemia"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07861-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07861-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07861-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T15:25:27Z","timestamp":1757258727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07861-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":158,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7861"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07861-0","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"531"}}